Boston Scientific Inks Pact With Aspect For Depression, Alzheimer’s Tests
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific will enhance its neurostimulation business and reap profits from future Aspect Medical SystemsBIS brain-monitoring technology for depression under a $25 mil. development deal announced May 23